Strong Financial Performance and Revised Guidance: - Pfizer reported Q2 2025 revenues of $14.7 billion, a 10% operational increase year-over-year. - Adjusted diluted EPS improved to $0.78, exceeding expectations. Full-year adjusted diluted EPS guidance was raised by $0.10 to a new range of $2.90 to $3.10.

Advancements in R&D Pipeline: - Pfizer is focusing on its R&D pipeline, highlighting promising products like Elrexfio for multiple myeloma and Sigvotatug Vedotin (SV) for non-small cell lung cancer, which are expected to drive future growth. - Elrexfio is positioned to capture a significant share of the growing multiple myeloma market projected to reach $44 billion by 2030.

Market Challenges from Pricing and Regulations: - Increased manufacturer discounts due to the IRA Medicare Part D redesign negatively impacted revenues by $825 million YoY, reflecting ongoing regulatory and pricing pressures. The company is actively engaging with policymakers on these issues.